Lifestance Health (LFST)

NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-10-23

$12.93+2.95%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Lifestance Health’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

0.0%

+10% or more+5%0%−5%−10% or less

0.22 → 0.22 EPS · FY ending Dec 31, 2027 · 5 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 24, 2026 to Oct 24, 2026: (new ÷ prior − 1). Contributor count changed from 5 to 5; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q3
EBITDA	$49M–$59Mnon-GAAP	—
FY 2026 · Q4
Revenue	—	438.56M
EPS	—	0.04
FY 2026 · Annual
Revenue	—	1.71B
EPS	—	0.161
FY 2027 · Annual
Revenue	—	1.96B
EPS	—	0.219

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Increase adjusted EBITDA to $200-$220 million in 2026	Profit rises with adjusted EBITDA near $220 million.	Improving	Adjusted EBITDA falls below $200 million in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Sustain quarterly revenue and profit growth	Quarterly revenue and profit keep improving.	Intact	Quarterly revenue or operating income falls below targets	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Grow revenue to $1.64-$1.68 billion in 2026	A primary condition in Lifestance Health's published investment case. The stated target is >= $1.64 billion.	Intact	Revenue falls below $1.64 billion in FY26	Revenue: $435.354M FY2026-Q2; GAAP. Published target: >= $1.64 billion. Target period is not explicitly aligned with this observation. Source published Aug 6, 2026435,354,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: f49c617a-9546-4421-9877-e0b7e6079b99. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$0.22

$0.39 → $0.22 · observed estimates

FY2027 revenue$1.96B

$1.90B → $1.96B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$0.39	$1,901,003,220	5 / 10
2026-07-25	$0.20	$1,901,593,659	5 / 8
2026-07-26	$0.39	$1,901,003,220	5 / 10
2026-07-27	$0.39	$1,901,283,620	5 / 10
2026-07-28	$0.39	$1,901,283,620	5 / 10
2026-07-29	$0.39	$1,901,283,620	5 / 10
2026-07-30	$0.39	$1,901,283,620	5 / 10
2026-07-31	$0.39	$1,901,283,620	5 / 10
2026-08-01	$0.20	$1,901,874,059	5 / 8
2026-08-02	$0.39	$1,902,063,620	5 / 10
2026-08-03	$0.39	$1,902,063,620	5 / 10
2026-08-04	$0.39	$1,902,063,620	5 / 10
2026-08-05	$0.39	$1,902,063,620	5 / 10
2026-08-06	$0.20	$1,902,654,059	5 / 8
2026-08-07	$0.20	$1,902,654,059	5 / 8
2026-08-08	$0.20	$1,902,654,059	5 / 8
2026-08-09	$0.20	$1,902,654,059	5 / 8
2026-08-10	$0.20	$1,902,654,059	5 / 8
2026-08-12	$0.20	$1,902,654,059	5 / 8
2026-08-13	$0.52	$1,938,149,530	5 / 10
2026-08-14	$0.20	$1,902,654,059	5 / 8
2026-08-15	$0.20	$1,902,654,059	5 / 8
2026-08-16	$0.20	$1,902,654,059	5 / 8
2026-08-17	$0.20	$1,902,654,059	5 / 8
2026-08-18	$0.20	$1,902,654,059	5 / 8
2026-08-19	$0.20	$1,902,654,059	5 / 8
2026-08-20	$0.22	$1,953,996,104	5 / 8
2026-08-21	$0.22	$1,953,996,104	5 / 8
2026-08-22	$0.22	$1,953,996,104	5 / 8
2026-08-23	$0.22	$1,953,996,104	5 / 8
2026-08-24	$0.22	$1,953,996,104	5 / 8
2026-08-25	$0.22	$1,953,996,104	5 / 8
2026-08-26	$0.22	$1,953,996,104	5 / 8
2026-08-27	$0.22	$1,953,996,104	5 / 8
2026-08-28	$0.22	$1,953,996,104	5 / 8
2026-08-29	$0.22	$1,953,996,104	5 / 7
2026-08-30	$0.22	$1,953,996,104	5 / 7
2026-08-31	$0.22	$1,953,996,104	5 / 7
2026-09-01	$0.22	$1,953,996,104	5 / 7
2026-09-02	$0.22	$1,953,996,104	5 / 7
2026-09-03	$0.22	$1,953,996,104	5 / 7
2026-09-04	$0.22	$1,953,996,104	5 / 7
2026-09-05	$0.22	$1,953,996,104	5 / 7
2026-09-06	$0.22	$1,953,996,104	5 / 7
2026-09-07	$0.22	$1,953,996,104	5 / 7
2026-09-08	$0.22	$1,953,996,104	5 / 7
2026-09-09	$0.22	$1,953,996,104	5 / 7
2026-09-10	$0.22	$1,953,996,104	5 / 7
2026-09-11	$0.22	$1,953,996,104	5 / 7
2026-09-12	$0.22	$1,953,996,104	5 / 7
2026-09-13	$0.22	$1,953,996,104	5 / 7
2026-09-14	$0.22	$1,953,996,104	5 / 7
2026-09-15	$0.22	$1,953,996,104	5 / 7
2026-09-16	$0.22	$1,953,996,104	5 / 7
2026-09-17	$0.22	$1,953,996,104	5 / 7
2026-09-18	$0.22	$1,953,996,104	5 / 7
2026-09-19	$0.22	$1,953,996,104	5 / 7
2026-09-20	$0.22	$1,953,996,104	5 / 7
2026-09-21	$0.22	$1,953,996,104	5 / 7
2026-09-22	$0.22	$1,953,996,104	5 / 7
2026-09-23	$0.22	$1,953,996,104	5 / 7
2026-09-24	$0.22	$1,953,996,104	5 / 7
2026-09-25	$0.22	$1,953,996,104	5 / 7
2026-09-26	$0.22	$1,953,996,104	5 / 7
2026-09-27	$0.22	$1,953,996,104	5 / 7
2026-09-28	$0.22	$1,953,996,104	5 / 7
2026-09-29	$0.22	$1,953,996,104	5 / 7
2026-09-30	$0.22	$1,953,996,104	5 / 7
2026-10-01	$0.22	$1,953,996,104	5 / 7
2026-10-02	$0.22	$1,953,996,104	5 / 7
2026-10-03	$0.22	$1,953,996,104	5 / 7
2026-10-04	$0.22	$1,953,996,104	5 / 7
2026-10-05	$0.22	$1,953,996,104	5 / 7
2026-10-06	$0.22	$1,956,056,104	5 / 7
2026-10-07	$0.22	$1,956,056,104	5 / 7
2026-10-08	$0.22	$1,956,056,104	5 / 7
2026-10-09	$0.22	$1,956,056,104	5 / 7
2026-10-10	$0.22	$1,956,056,104	5 / 7
2026-10-11	$0.22	$1,956,056,104	5 / 7
2026-10-12	$0.22	$1,956,056,104	5 / 7
2026-10-13	$0.22	$1,956,056,104	5 / 7
2026-10-14	$0.22	$1,956,056,104	5 / 7
2026-10-15	$0.22	$1,956,056,104	5 / 8
2026-10-16	$0.22	$1,956,056,104	5 / 8
2026-10-17	$0.22	$1,956,056,104	5 / 8
2026-10-18	$0.22	$1,956,036,104	5 / 8
2026-10-19	$0.22	$1,956,036,104	5 / 8
2026-10-20	$0.22	$1,956,036,104	5 / 8
2026-10-21	$0.22	$1,956,036,104	5 / 8
2026-10-22	$0.22	$1,956,036,104	5 / 8
2026-10-23	$0.22	$1,956,036,104	5 / 8
2026-10-24	$0.22	$1,956,036,104	5 / 8

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	9	1
2026-06-01	9	2
2026-07-01	9	2
2026-08-01	9	2
2026-09-01	9	2
2026-10-01	9	2

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 9 Buy / Strong Buy · 2 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades1 maintains

Recent actions · Sep 25–Oct 24 · 1 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

KeyBancOct 5 · prior Jul 13

$13.00 → $15.00+15.4%

$0$8.25$16.50

1 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Increase adjusted EBITDA to $200-$220 million in 2026Direct metric needs a verified mapping
Sustain quarterly revenue and profit growthDirect metric needs a verified mapping
Grow revenue to $1.64-$1.68 billion in 2026Revenue: $435.354M

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.6%Typical daily move · historical

Downside history

-17.1%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Lifestance Health outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

LFST is a high-growth healthcare business with improving operating performance, but it is not yet profitable on the evidence provided. Its long-term thesis is intact, supported by recent results and higher guidance, though confidence is medium.

What's priced into Lifestance Health

LFST is valued at a premium to peers, and the valuation signal points to expectations that depend partly on a re-rating, or a change in how the market values the business. The expectations gap is negative, but model confidence is low, so the evidence on what is already priced in is limited; no valuation fragility flags are present.

What the fundamentals likely do

Near term, management’s stated goals are on track: Q2 2026 revenue rose 26% year over year, adjusted EBITDA rose 94%, and full-year guidance for both was raised. Clinician numbers and visit volumes also increased, but the business remains loss-making, and the snapshot notes a history of recent misses despite a low near-term miss-risk assessment.

What Lifestance Health hinges on

The multi-year view depends on LFST sustaining revenue growth and turning strong adjusted EBITDA progress into durable profitability. Near term, a guidance cut or further weakening in jobs data could pressure the business outlook, while continued earnings strength and higher guidance from healthcare peers would support sector momentum.